At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
,_Thyrocare_256_384.jpg)
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The new facility is expected to generate 500-600 new jobs in the region
The state-of-the-art facility is expected to be commissioned over the next three years
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
This recognition demonstrate excellence in intellectual property (IP) value creation.
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Subscribe To Our Newsletter & Stay Updated
